Biogen Idec, Fumapharm deal

BIIB agreed to acquire Fumapharm for an undisclosed amount of stock. The deal gives BIIB full ownership of BG-12, which has completed Phase III testing for moderate and severe psoriasis and Phase II testing for relapsing-remitting multiple sclerosis (RRMS). Under a 2003 deal, BIIB already had exclusive worldwide development and marketing rights to BG-12, a second-generation oral fumarate derivative, excluding Germany. ...